Filtered By:
Management: Electronic Health Records (EHR)
Procedure: Transplants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 85 results found since Jan 2013.
CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study
In conclusion, the safety and efficacy of CAR T-cell therapy were not affected in patients with rheumatic autoimmune diseases. Moreover, they achieved better biochemical control of underlying rheumatic diseases.PMID:37604871 | DOI:10.1038/s41409-023-02086-1
Source: Cancer Control - August 21, 2023 Category: Cancer & Oncology Authors: Jiasheng Wang Akram Alkrekshi Srilatha Dasari Hsin-Ti Cindy Lin Dina Elantably Abdul Rahman Al Armashi Source Type: research
The improving Medication Adherence in Adolescents and young adults following Liver Transplantation (iMALT) multisite trial: Design and trial implementation considerations
DISCUSSION: Improving Medication Adherence in adolescent Liver Transplant includes several innovative design elements. The use of a validated, objective adherence index to survey a large cohort of transplant recipients allows the teams to avoid bias inherent in both convenience sampling and referral-based recruitment and enroll only patients whose computed index indicates substantially increased risk of rejection. The remote intervention paradigm helps to engage patients who are by definition hard to engage. The use of an objective, masked medical (rather than behavioral) outcome measure reduces the likelihood of biases re...
Source: Clinical Trials - June 3, 2023 Category: Research Authors: Eyal Shemesh Sarah Duncan-Park George Mazariegos Rachel Annunziato Ravinder Anand Miguel Reyes-Mugica Jeff Mitchell Benjamin L Shneider for iMALT Source Type: research
Novel computational methods on electronic health record yields new estimates of transfusion-associated circulatory overload in populations enriched with high-risk patients
DISCUSSION: While TACO is a serious AR, events remained rare, even in populations enriched with high-risk patients. Novel computational methods can be used to find and continually surveil for transfusion ARs. Results suggest that patients with history or presence of coagulopathy and organ transplant should be carefully monitored to mitigate potential risks of TACO.PMID:37248741 | DOI:10.1111/trf.17447
Source: Transfusion - May 30, 2023 Category: Hematology Authors: Michelle Wang Gregory M Goldgof Ayan Patel Barbee Whitaker Artur Belov Brian Chan Evan Phelps Benjamin Rubin Steven Anderson Atul J Butte Source Type: research
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
Clin Lymphoma Myeloma Leuk. 2023 Mar 30:S2152-2650(23)00112-X. doi: 10.1016/j.clml.2023.03.015. Online ahead of print.ABSTRACTIn newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) improved overall survival (OS) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). As clinical trial and real-world populations may differ, real-world treatment characteristics and OS (rwOS) were assessed for patients with stage III/IV cHL treated with frontline ABVD. This retrospective, observational analysis of deidentified electronic health record data (1/...
Source: Clinical Lymphoma and Myeloma - April 30, 2023 Category: Cancer & Oncology Authors: Allison Winter Nicholas Liu Andy Surinach Michelle Fanale Kristina S Yu Mayur Narkhede Source Type: research
Multi-omics profiling for health
Mol Cell Proteomics. 2023 Apr 27:100561. doi: 10.1016/j.mcpro.2023.100561. Online ahead of print.ABSTRACTThe world has witnessed a steady rise in both non-infectious and infectious chronic diseases, prompting a cross-disciplinary approach to understand and treat disease. Current medical care focuses on treating people after they become patients rather than to preventing illness, leading to high costs in treating chronic and late-stage diseases. Additionally, a 'one-size-fits all' approach to healthcare does not take into account individual differences in genetics, environment, or lifestyle factors, decreasing the number of...
Source: Molecular and Cellular Proteomics : MCP - April 29, 2023 Category: Molecular Biology Authors: Mohan Babu Michael Snyder Source Type: research
Fight Aging! Newsletter, February 27th 2023
This study tested the hypothesis that ischemic vascular repair in aging by Ang-(1-7) involves attenuation of myelopoietic potential in the bone marrow and decreased mobilization of inflammatory cells.
Young or Old male mice of age 3-4 and 22-24 months, respectively, received Ang-(1-7) for four weeks. Myelopoiesis was evaluated in the bone marrow (BM) cells by carrying out the colony forming unit (CFU-GM) assay followed by flow cytometry of monocyte-macrophages. Expression of pro-myelopoietic factors and alarmins in the hematopoietic progenitor-enriched BM cells was evaluated. Hindlimb ischemia (HLI) was induced by ...
Source: Fight Aging! - February 26, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience
CONCLUSION: Our study shows that PT-Cy was associated with an increased risk of EMC. The predictive value of EMC for relapse remains unclear and may depend on the underlying disease, which should be validated in a larger cohort.PMID:36842566 | DOI:10.1016/j.trim.2023.101808
Source: Transplant Immunology - February 26, 2023 Category: Transplant Surgery Authors: Fieke W Hoff Stephen S Chung Prapti A Patel Naveen Premnath Jude Khatib Mirjana Tadic-Ovcina Abeer AhmedRabie Debra Helton Selamawit Yohannes Jaime Shahan Hetalkumari Patel Praveen Ramakrishnan Geethakumari Madhuri Vusirikala Robert H Collins Yazan F Mada Source Type: research
